STAR*D: Has it taught us anything about the management of depression?

Australasian Psychiatry

Volumn 17, Issue 5, 2009, Pages 360-364

  Castle, David ^a   Schweitzer, Isaac ^a   Tiller, John ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antidepressants depression; STAR*D; Treatment

Indexed keywords

AMFEBUTAMONE; BUSPIRONE; CITALOPRAM; LITHIUM; MIRTAZAPINE; NORTRIPTYLINE; SERTRALINE; TRANYLCYPROMINE; VENLAFAXINE; ANTIDEPRESSANT AGENT;

AUSTRALIA AND NEW ZEALAND; COGNITIVE THERAPY; COMMUNITY MENTAL HEALTH; DEPRESSION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HAMILTON SCALE; HUMAN; PATIENT DECISION MAKING; RATING SCALE; REMISSION; REVIEW; SCORING SYSTEM; TREATMENT FAILURE; TREATMENT RESPONSE; ADOLESCENT; ADULT; AGED; ARTICLE; FEMALE; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATIENT PARTICIPATION; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PATIENT PARTICIPATION; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION;

EID: 70849084594     PISSN: 10398562     EISSN: 14401665     Source Type: Journal    
DOI: 10.1080/10398560903176958     Document Type: Review

References (20)

1. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005; 353: 1209-1223.
2. Sachs GS, Thase ME, Otto MW et al. Rationale, design, and methods of the Systematic Treatment Enhancement Program for Bipolar Disorders (STEP-BD). Biological Psychiatry 2003; 53: 1028-1042.
3. Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry 2006; 163: 1905-1917.
4. Hamilton M. Development of a scale for primary depressive illness. British Journal of the Society of Clinical Psychologists 1967; 6: 278-296.
5. Trivedi MH, Rush AJ, Ibrahim HM et al. The Inventory of Depressive Symptomatology, clinician rating (IDS-C) and self-report (IDS-SR), and Quick Inventory of Depressive Symptomatology, clinician rating (QIDS-C) and self-report (QIDS-SR) in public sector patients with mood disorders: A psychometric evaluation. Psychological Medicine 2004; 34: 73-84.
6. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychological Medicine 1996; 26: 477-486.
7. Ritsner M, Kurs R, Ratner Y, Gibel A. Condensed version of the Quality of Life Scale for schizophrenia for use in outcome studies. Psychiatry Research 2005; 135: 65-75.
8. Parker G, Manicavasagar V. Modelling and Managing the Depressive Disorders. Cambridge: Cambridge University Press, 2005.
9. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. British Journal of Psychiatry 2001; 178: 234-241.
10. Elkin I, Watkins JT, Imber SD et al. National Institute of Mental Health treatment of depression collaborative research program. General effectiveness of treatments. Archives of General Psychiatry 1989; 46: 971-982.
11. Rapaport MH, Gharabawi GM, Canuso CM et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 2006; 31: 2505-2513.
12. Patakar AA, Peindl K, Mago R et al. An open-label, rater blinded, augmentation study of aripiprazole in treatment-resistant depression. Journal of Clinical Psychiatry 2006; 8: 82-87.
13. Kennedy SH, Lam RW, Nutt DJ, Thase ME. Treating Depression Effectively: Applying Clinical Guidelines. London: Informa Heathcare, 2007.
14. Lam RW, Mok H. Depression. Oxford: Oxford University Press, 2008.
15. Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive Therapy of Depression. New York: Guildford Press, 1979.
16. Frank E, Grochocinski VJ, Spanier CA et al. Interpersonal psychotherapy and antidepressant medication: evaluation of a sequential treatment strategy in women with recurrent major depression. Journal of Clinical Psychiatry 2000; 61: 51-57.
17. Wisniewski SR, Fava M, Trivedi MH et al. Acceptability of second-step treatments to depressed outpatients: A STAR*D report. American Journal of Psychiatry 2007; 164: 753-760.
18. Trivedi MH, Rush AJ, Wishniewski SR et al. Evaluation of outcomes with citalopram for depression using Measurement-Base Care in STAR*D: Implications for clinical practice. American Journal of Psychiatry 2006; 163: 28-40.
19. Thase ME, Friedman ES, Biggs MM et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: A STAR*D report. American Journal of Psychiatry 2007; 164: 739-752.
20. Warden D, Rush AJ, Wisniewski SR et al. What predicts attrition in second step medication treatments for depression?: A STAR*D report. International Journal of Neuropsychopharmacology 2009; 12: 459-473.